Results from an artificial intelligence project have identified many existing drugs that could reduce sight loss from age-related macular degeneration (AMD).

Carried out by Action Against AMD and artificial intelligence company BenevolentAI, the research discovered that there are seven existing drugs either in development or in use for other conditions that could be used to treat AMD. Researchers also highlighted new gene targets and drugs for further investigation.

Dr Wen Hwa Lee, chief executive for Action Against AMD said: ‘It’s really promising that we have identified current drugs that may have a positive effect on macular degeneration. Our next step will be to confirm which of these drugs have the potential to slow progression of the disease and reduce sight loss for people with this condition.’

Dr Jackie Hunter, board director at BenevolentAI added: ‘It has been a very productive partnership with Action Against AMD and we are delighted to have contributed some promising new research in age-related macular degeneration.’